Pharmacogenetics of human androgens and prostate cancer - An update

Giuseppe Novelli, Katia Margiotti, Anna Maria Chiocca, Enrico Spera, Francesco Micali, Juergen K V Reichardt

Research output: Contribution to journalArticlepeer-review


Prostate cancer is the most common non-skin cancer in the US; it is the second leading cause of death from cancer among US men, and the seventh leading cause of death in the US. This review examines the recent biochemical and pharmacogenetic literature related to prostate cancer, specifically that which focused on constitutional ('germline') single nucleotide polymorphisms at 'functional candidate' genes for prostate cancer. The investigations summarized in this review demonstrate the need to study the molecular genetics at these loci to rationally develop personalized medicine. In addition, the identification of somatic pharmacogenetic alterations in one of these loci suggests that this may also be a fruitful field of investigations with important clinical applications. Pharmacogenomic investigations of constitutional and tumor DNA may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of prostate cancer. 2004

Original languageEnglish
Pages (from-to)283-294
Number of pages12
Issue number3
Publication statusPublished - Apr 2004


  • Androgen receptor
  • AR
  • Chemoprevention
  • CYP17
  • CYP19
  • Finasteride
  • HSD3B2
  • Personalized medicine
  • Pharmacogenetics
  • Prostate cancer
  • Single nucleotide polymorphism
  • SNP
  • SRD5A2
  • Steroid 5α-reductase
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)


Dive into the research topics of 'Pharmacogenetics of human androgens and prostate cancer - An update'. Together they form a unique fingerprint.

Cite this